SCHEMBL4942355

SCHEMBL4942355

CC(=O)CC(=O)N1C/C(=N/OCc2ccc(Cl)c(Cl)c2)C[C@H]1C(=O)NC1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.36
DPP4 P27487 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
SIGMAR1 Q99720 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
OPRK1 P41145 9/20 0.35
GRM2 Q14416 1/20 0.35
GRM3 Q14832 1/20 0.35
P2RX7 Q99572 1/20 0.35
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
NFKB1 P19838 1/20 0.34
CYP2C19 P33261 1/20 0.34
OPRD1 P41143 1/20 0.34
HIF1A Q16665 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4942360 1.00 MCHR1 (0.36) MCHR1DPP4DPP7SIGMAR1MEN1
SCHEMBL6969682 0.93 MCHR1 (0.38) MCHR1DPP4DPP7SIGMAR1MEN1
SCHEMBL4944176 0.93 MCHR1 (0.38) MCHR1DPP4DPP7SIGMAR1MEN1
SCHEMBL4944181 0.93 MCHR1 (0.38) MCHR1DPP4DPP7SIGMAR1MEN1
SCHEMBL6977855 0.93 MCHR1 (0.38) MCHR1DPP4DPP7SIGMAR1MEN1
SCHEMBL4940085 0.91 OPRK1 (0.39) MCHR1DPP4DPP7SIGMAR1OPRK1
SCHEMBL4940074 0.91 OPRK1 (0.39) MCHR1DPP4DPP7SIGMAR1OPRK1
SCHEMBL4942149 0.83 SIGMAR1 (0.39) DPP4DPP7SIGMAR1MEN1KMT2A
SCHEMBL4942156 0.83 SIGMAR1 (0.39) DPP4DPP7SIGMAR1MEN1KMT2A
SCHEMBL4942999 0.75 CAPN1 (0.39) CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7211601-B2 Pharmaceutically active pyrrolidine derivatives APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2007-05-01 US claimed
EP-1268419-B1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2006-06-21 EP claimed
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors MERCK SERONO SA (CH) 2003-09-11 US claimed
US-20080167318-A1 Pharmaceutically active pyrrolidine derivatives APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-07-10 US disclosed
US-7211601-B2 Pharmaceutically active pyrrolidine derivatives APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2007-05-01 US disclosed
EP-1268419-B1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2006-06-21 EP disclosed
EP-1268418-B1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2006-06-14 EP disclosed
US-7018988-B2 Pharmaceutically active pyrrolidine derivatives as Bax inhibitors APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-03-28 US disclosed
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives MERCK SERONO SA (CH) 2003-11-13 US disclosed
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors MERCK SERONO SA (CH) 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives OXTR, CNR1, PRLHR MCHR1 420/4885DPP4 4848/4885DPP7 4418/4885
US-20080167318-A1 Pharmaceutically active pyrrolidine derivatives OXTR, PRLHR, NR0B1 MCHR1 422/4885DPP4 4838/4885DPP7 4338/4885
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors SUCNR1, PYCR1, GLS MCHR1 1400/4885DPP4 4658/4885DPP7 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.